Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy | Zendy

Raúl Vélez-Montoya | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy

Author(s) -

Raúl Vélez-Montoya

Publication year - 2008

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s2686

Subject(s) - medicine , capsulotomy , ophthalmology , posterior capsule opacification , bevacizumab , visual acuity , posterior capsulotomy , macular edema , intraocular lens , capsule , diabetic retinopathy , posterior segment of eyeball , phacoemulsification , surgery , diabetes mellitus , botany , chemotherapy , biology , endocrinology

We reported a 75-year-old diabetic man, who developed opacification and neovascularization of the posterior capsule after extracapsular cataract extraction and posterior chamber intraocular lens implantation. The patient was treated with two injections of 2.5 mg of intravitreal bevacizumab. The treatment produced an important regression of the posterior capsular new vessels, allowing us to perform a successful Nd:YAG capsulotomy, clearing the visual axis and improving the visualization of the posterior pole. Even though, best corrected visual acuity was 20/200 due to diabetic macular edema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research